Lyrica: Uses, dosage, side effects, warnings & patient reviews

What is Lyrica (Pregabalin)?

Lyrica (pregabalin) is a prescription medication classified as a gabapentinoid and a Schedule V controlled substance. It is structurally related to the antiepileptic drug gabapentin but has more predictable pharmacokinetics.

The drug binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system. This action reduces the release of several excitatory neurotransmitters and is believed to contribute to its analgesic and anticonvulsant effects. Pregabalin is not significantly metabolized and is eliminated primarily by the kidneys, making its clearance dependent on kidney function.

Its major medical uses include treatment of neuropathic pain conditions. For comprehensive information on nerve damage and pain, see our resource on peripheral neuropathy.

Brand and Generic Availability

Lyrica is the brand name for pregabalin. Generic pregabalin capsules and oral solution are available. FDA-approved generics are considered bioequivalent to the brand-name product; individual response can still vary, so follow your prescriber’s guidance if switching products.

How to Take Lyrica

Take Lyrica exactly as prescribed. Dosing depends on the condition being treated, kidney function, and how well the medication is tolerated.

Administration

Lyrica (pregabalin) is taken orally, with or without food. The oral solution should be measured with the provided dosing syringe or an accurate measuring device. Food does not meaningfully change overall absorption, but some people find taking doses consistently with meals improves tolerability.

Dosage Initiation and Titration

Treatment is typically started at a lower dose to assess tolerability. The dose may then be increased (titrated) based on individual response and side effects. Maximum recommended daily doses vary by indication and patient factors; see the dosage table and follow the official prescribing information.

Discontinuation

Abrupt discontinuation of Lyrica may lead to withdrawal symptoms. When discontinuing treatment, the dose should be tapered gradually over a minimum of one week. Patients should not adjust their dose or stop taking the medication without consulting their prescriber.

Side Effects of Lyrica

Adverse reactions to pregabalin are common and often involve the central nervous system. The incidence and severity of side effects may be dose-dependent.

What is Lyrica Used For?

Pregabalin is indicated for specific medical conditions when prescribed by a healthcare provider.

FDA-Approved Indications

• Neuropathic Pain: Management of neuropathic pain associated with diabetic peripheral neuropathy and management of postherpetic neuralgia (nerve pain following shingles).
• Fibromyalgia: Management of fibromyalgia, a chronic pain syndrome. For more on chronic pain management, visit our pain relief category.
• Epilepsy: Adjunctive therapy for the treatment of partial-onset seizures in adults.

Off-Label Use

Pregabalin is also used off-label under physician supervision for other conditions, most notably generalized anxiety disorder (GAD) in some countries. It is not FDA-approved for this indication in the United States. Information on anxiety treatments can be found in our anxiety medication category.

Important Safety Concerns and Considerations

Abuse, Dependence, and Withdrawal

Pregabalin is a Schedule V controlled substance due to its potential for misuse, psychological dependence, and physical dependence. Euphoria and other subjective effects have been reported, particularly in individuals with a history of substance use disorder. Patients with a history of alcoholism or drug misuse may require closer monitoring. Abrupt discontinuation after prolonged use can lead to a withdrawal syndrome including insomnia, nausea, headache, diarrhea, anxiety, hyperhidrosis, and rarely, seizures. Discontinuation typically requires a gradual taper under medical supervision.

Suicidal Behavior and Ideation

Antiepileptic drugs (AEDs), including pregabalin, may increase the risk of suicidal thoughts or behavior in some patients. This risk has been observed early in treatment and can persist during therapy. Patients, caregivers, and families should watch for new or worsening depression, unusual changes in mood or behavior, or suicidal thoughts, and report concerning changes promptly to a healthcare provider. For related information, see our depression medication category.

Peripheral Edema and Cardiovascular Risk

Pregabalin can cause peripheral edema (swelling of the hands and feet) and weight gain. This may be of particular concern in patients with pre-existing heart disease or congestive heart failure (CHF), as fluid retention may worsen symptoms in some individuals.

Renal Impairment

Pregabalin is eliminated primarily by renal excretion. Dosage reduction is required in patients with impaired renal function (creatinine clearance < 60 mL/min). Without dose adjustment, drug accumulation can increase the risk of adverse effects.

Hypersensitivity and Angioedema

Serious hypersensitivity reactions, including angioedema (swelling of the face, mouth, tongue, and larynx), have been reported. If these symptoms occur, stop taking pregabalin and seek emergency medical care.

Critical Warnings for Lyrica Use

Increased Risk of Suicidal Thoughts and Behavior

Patients treated with antiepileptic drugs (AEDs) for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or unusual changes in mood or behavior. This increased risk was observed as early as one week after starting drug therapy. The absolute risk, while increased, remains numerically small.

Respiratory Depression

Post-marketing reports and clinical data indicate that pregabalin, especially when used with central nervous system (CNS) depressants (including opioids), may increase the risk of serious respiratory depression. Risk may be higher in older adults and in people with underlying respiratory conditions. If concomitant use is necessary, clinicians may use the lowest effective doses and recommend closer monitoring.

Dizziness and Somnolence

Pregabalin can cause dose-related dizziness and somnolence. These effects can impair the ability to perform tasks requiring mental alertness or physical coordination, such as driving or operating machinery. Patients should avoid these activities until they have enough experience to understand how the medication affects them. The risk is higher during initial titration and with dose increases.

Withdrawal of Antiepileptic Drugs (AEDs)

As with other AEDs, pregabalin should be withdrawn gradually to minimize the potential of increased seizure frequency in patients with seizure disorders. For patients without epilepsy, abrupt withdrawal may lead to symptoms such as insomnia, nausea, headache, and anxiety.

Tumorigenic Potential

In standard preclinical in vivo studies, pregabalin was associated with an increased incidence of hemangiosarcoma and other vascular tumors in mice. The clinical significance of this finding is unknown.

Lyrica Dosage Information

Dosing of pregabalin is individualized based on indication, renal function, and tolerability. The table below is for general information and does not replace a prescriber’s dosing instructions.

The following table outlines standard initial and maximum doses for patients with normal renal function (creatinine clearance ≥60 mL/min).

Important Administration Notes

• Titration: Dose increases are typically made gradually based on response and tolerability. The timing and target dose depend on the indication.
• Renal Impairment: Dosage must be reduced in patients with creatinine clearance below 60 mL/min. Refer to the full prescribing information for specific dosing tables.
• Missed Dose: If a dose is missed, it should be taken as soon as remembered unless it is almost time for the next dose. Double doses should not be taken to make up for a missed dose.
• Discontinuation: Taper gradually over a minimum of one week. Do not stop abruptly.

Available Strengths

Pregabalin capsules are available in the following strengths: 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg, and 300 mg. An oral solution (20 mg/mL) is also available for dosing adjustment.

Drug Interactions with Lyrica

Pregabalin has a low potential for pharmacokinetic drug interactions because it is not significantly metabolized and does not induce or inhibit major CYP450 enzymes. Its primary interactions are pharmacodynamic.

Gabapentin Comparison

Pregabalin is often compared to gabapentin (Neurontin), a related compound. While both are gabapentinoids, pregabalin has more predictable, linear pharmacokinetics with higher oral bioavailability. Side effect profiles overlap, and medication choice and dosing should follow clinician guidance.

Additional Information

Storage and Handling

Store Lyrica (pregabalin) capsules and oral solution at room temperature between 20°C to 25°C (68°F to 77°F), with excursions permitted between 15°C to 30°C (59°F to 86°F). The oral solution should be stored in its original container. Keep all medications out of the sight and reach of children and pets.

Mechanism of Action Details

Pregabalin binds with high affinity to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system. This binding reduces calcium influx at nerve terminals, which can reduce the release of excitatory neurotransmitters, including glutamate, norepinephrine, and substance P. This action is believed to contribute to its effects in neuropathic pain and seizure disorders.

Reporting Side Effects

Patients and caregivers can report suspected side effects to a national regulatory authority (for example, in the U.S., the FDA MedWatch program). Reporting supports ongoing safety surveillance.

References and Medical Sources

The clinical information on this page is based on the official prescribing information and peer-reviewed medical literature.

1. U.S. Food and Drug Administration (FDA). Lyrica (pregabalin) Capsules CV Prescribing Information & Medication Guide. [Revised July 2021]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021446s035,022488s013lbl.pdf
2. DailyMed (U.S. National Library of Medicine). Pregabalin / Lyrica labeling information (drug label repository).
   https://dailymed.nlm.nih.gov/dailymed/
3. MedlinePlus. Pregabalin. U.S. National Library of Medicine. [Updated May 2022].
   https://medlineplus.gov/druginfo/meds/a605045.html
4. Official product website (patient information). Lyrica official site.
   https://www.lyrica.com/
5. FDA Drug Safety Communication. Serious breathing problems with gabapentin and pregabalin (gabapentinoids), including when used with CNS depressants.
   https://www.fda.gov/drugs/drug-safety-and-availability
6. Finnerup, N. B., et al. “Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis.” The Lancet Neurology, vol. 14, no. 2, 2015, pp. 162–173.